- Home
- IMTX vs BME Comparison
IMTX vs BME Comparison
Compare IMTX & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- BME
- Stock Information
- Founded
- IMTX N/A
- BME 2005
- Country
- IMTX Germany
- BME United States
- Employees
- IMTX N/A
- BME N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- BME Trusts Except Educational Religious and Charitable
- Sector
- IMTX Health Care
- BME Finance
- Exchange
- IMTX Nasdaq
- BME Nasdaq
- Market Cap
- IMTX 559.1M
- BME 525.3M
- IPO Year
- IMTX N/A
- BME N/A
- Fundamental
- Price
- IMTX $4.60
- BME $40.21
- Analyst Decision
- IMTX Strong Buy
- BME
- Analyst Count
- IMTX 4
- BME 0
- Target Price
- IMTX $16.67
- BME N/A
- AVG Volume (30 Days)
- IMTX 1.2M
- BME 34.0K
- Earning Date
- IMTX 03-20-2025
- BME 01-01-0001
- Dividend Yield
- IMTX N/A
- BME 6.26%
- EPS Growth
- IMTX N/A
- BME N/A
- EPS
- IMTX N/A
- BME 1.44
- Revenue
- IMTX $128,824,447.00
- BME N/A
- Revenue This Year
- IMTX $116.22
- BME N/A
- Revenue Next Year
- IMTX N/A
- BME N/A
- P/E Ratio
- IMTX N/A
- BME $28.37
- Revenue Growth
- IMTX 52.53
- BME N/A
- 52 Week Low
- IMTX $4.48
- BME $35.53
- 52 Week High
- IMTX $13.77
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- IMTX 27.20
- BME 50.67
- Support Level
- IMTX $4.85
- BME $40.01
- Resistance Level
- IMTX $5.25
- BME $40.55
- Average True Range (ATR)
- IMTX 0.28
- BME 0.38
- MACD
- IMTX -0.01
- BME -0.11
- Stochastic Oscillator
- IMTX 8.96
- BME 17.09
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.